You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 2, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
Fabian Heinemann1, Gerald Birk2, Birgit Stierstorfer2
1Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397, Biberach an der Riß, Germany. fabian.heinemann@boehringer-ingelheim.com.
Automated deep learning models using convolutional neural networks (CNNs) can now score liver disease features like ballooning, inflammation, steatosis, and fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These AI-driven scores show strong agreement with human pathologists.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: